Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

171.28USD
28 Jul 2016
Change (% chg)

-- (--)
Prev Close
$171.28
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,869,410
52-wk High
$181.81
52-wk Low
$130.09

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $128,668.50
Shares Outstanding(Mil.): 751.22
Dividend: 1.00
Yield (%): 2.34

Financials

  AMGN.O Industry Sector
P/E (TTM): 18.12 42.74 36.62
EPS (TTM): 9.45 -- --
ROI: 11.17 -9.63 14.52
ROE: 26.15 -9.94 15.68

Amgen again raises 2016 forecast in display of confidence

Amgen Inc on Wednesday posted higher-than-expected second-quarter profit on strong drug sales and again raised its full-year forecast in a clear signal of management confidence in the business.

Jul 27 2016

REFILE-UPDATE 2-Amgen again raises 2016 forecast in display of confidence

July 27 Amgen Inc on Wednesday reported higher-than-expected second-quarter profit on increased sales of its blockbuster rheumatoid arthritis drug Enbrel and newer medicines, and the company again raised its full-year forecast.

Jul 27 2016

Amgen 2nd-quarter profit tops Street view, raises 2016 forecast

July 27 Amgen Inc on Wednesday reported higher-than-expected second-quarter profit on increased sales of its blockbuster rheumatoid arthritis drug Enbrel and newer medicines, and the company again raised its full-year forecast.

Jul 27 2016

BRIEF-Amgen declares quarterly dividend of $1 per share

* Board of directors declared a $1.00 per share dividend for q3 of 2016 Source text for Eikon: Further company coverage: )

Jul 22 2016

BRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA

* Amgen and UCB submit biologics license application for romosozumab to the FDA

Jul 22 2016

Amgen, Allergan biosimilar found as effective as Roche cancer drug

Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

Jul 21 2016

Amgen, Allergan biosimilar found as effective as Roche cancer drug

July 21 Amgen Inc and Allergan Plc said their copycat version of Roche Holding AG's blockbuster cancer treatment, Herceptin, was found as effective as the original in a late-stage study.

Jul 21 2016

BRIEF-Allergan, Amgen collaborating on development, commercialization of four oncology biosimilars

* In neoadjuvant phase of study, which included chemotherapy, there were more serious adverse events reported in ABP 980 group

Jul 21 2016

BRIEF-Amgen announces settlement of securities litigation

* Settlement class consists of purchasers of Amgen's publicly-traded securities during period from April 22, 2004, through May 10, 2007

Jul 20 2016

FDA panel backs Valeant psoriasis drug with risk program

Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

Jul 19 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.